SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 9,111.44 |
| Enterprise Value ($M) | 9,881.02 |
| Book Value ($M) | 3,407.88 |
| Book Value / Share | 15.77 |
| Price / Book | 2.67 |
| NCAV ($M) | -394.62 |
| NCAV / Share | -1.83 |
| Price / NCAV | -23.09 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | 0.02 |
| Return on Assets (ROA) | 0.02 |
| Return on Equity (ROE) | 0.03 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 2.83 |
| Current Ratio | 3.37 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 1,742.87 |
| Assets | 5,545.37 |
| Liabilities | 2,137.49 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 1,978.21 |
| Operating Income | 498.80 |
| Net Income | 83.59 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 673.55 |
| Cash from Investing | -249.23 |
| Cash from Financing | -422.90 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | Wellington Management Group Llp | 10.70 | 9.60 | |
| 13G | BlackRock, Inc. | 10.20 | 2.53 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 248,734 | 1,687,938 | 14.74 | |
| 230,340 | 1,521,951 | 15.13 | |
| 254,109 | 1,268,996 | 20.02 | |
| 215,305 | 909,359 | 23.68 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| PBH – Prestige Consumer Healthcare Inc. | PFE – Pfizer Inc. |
| PRGO – Perrigo Company plc | RCUS – Arcus Biosciences, Inc. |
| RFL – Rafael Holdings, Inc. |
Financial data and stock pages provided by
Fintel.io